Union Minister Suresh Angadi dies of covid; PM, President express grief

Agencies
September 23, 2020

angadi.png

New Delhi, Sept 23: Junior Railways Minister Suresh Angadi has died nearly two weeks after he tested positive for coronavirus infection. He was admitted to AIIMS in Delhi after his condition worsened. He was the first Union Minister and the fourth MP to die due to COVID-19 infection.

Born in 1955, the BJP leader from Belgaum district in Karnataka has held several positions in the party in his long political career. He started as BJP vice president in Belgaum in 1996, and worked his way up.

He was elected MP in the Lok Sabha election in 2004, and again in 2009. He was elected for a third term in 2014, when the BJP came to power in the centre, and for a fourth term in the general election last year, after which he was made Union Minister of State for Railways.

President Ram Nath Kovind tweeted, "Shocked to know the passing away of Shri Suresh Angadi, Union Minister of State of Railways. An amiable leader Shri Angadi worked tirelessly for the people of his constituency, Belagavi and Karnataka."

Prime Minister Narendra Modi also tweeted his condolences.

"Shri Suresh Angadi was an exceptional Karyakarta, who worked hard to make the Party strong in Karnataka. He was a dedicated MP and effective Minister, admired across the spectrum. His demise is saddening. My thoughts are with his family and friends in this sad hour. Om Shanti," PM Modi tweeted.

Former Prime Minister and Janata Dal (Secular) chief HD Deve Gowda tweeted, "I am shocked and deeply saddened by the demise of Union Minister of State for Railways and four-term MP from Belagavi Shri. Suresh Angadi. He was like a younger brother to me. I feel terrible losing him. This is an unbearable loss to our nation."

Mr Angadi was a law graduate. He is survived by his wife and two daughters.

India has been reporting coronavirus cases upwards of 70,000 daily for the past few weeks. Other MPs who have died due to coronavirus infection are H Vasanthkumar, Ashok Gasti and Balli Durga Prasad Rao.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
October 28,2020

vaccine.jpg

Bengaluru, Oct 28: Drugmaker Dr Reddy's Laboratories Ltd on Wednesday rolled out a preliminary timeline for the India trials of Russia's coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.

Chief Executive Officer Erez Israeli said enrolment to the mid-stage trial of the Sputnik V vaccine will start in the next few weeks and the trial was likely to end by December.

"(Phase 3 trial) can be over as fast as the end of March, but it could go into April or May," Israeli said on a post-earnings press briefing, adding the timeline will depend on the Phase 2 trial results and further approvals from authorities.

With 8 million Covid-19 infections and second only to the United States, India is pinning its hopes on a vaccine to stem the spread of the pandemic.

The ongoing festive season and a state assembly election are seen by healthcare experts as adding to the challenges in containing the outbreak.

The Hyderabad-based company had received renewed approval for late-stage clinical trials in India of the Sputnik V vaccine earlier this month, after initially signing a deal with the Russian Direct Investment Fund in September.

The company expects to enrol 100 participants for the mid-stage trial and 1,500 people for the late-stage.

Shares of the company closed 2.9% lower at 4,951 rupees in a weak Mumbai market after Dr Reddy's reported a 30.3% fall in consolidated net profit after tax from a year earlier. Net sales, however, jumped to 47.77 billion rupees from 39.98 billion rupees a year ago.

The drugmaker, which last week isolated all its data centre services as a preventive measure following a cyberattack, said it was a ransomware attack, but was yet to ascertain if any personal information was accessed.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
October 30,2020

Farooq_Abdullah.jpg

Jammu and Kashmir, Oct 30: The National Conference (NC) on Friday claimed that authorities in Jammu and Kashmir prevented its president Farooq Abdullah from leaving his residence to offer prayers at the Hazratbal shrine here on the occasion of Milad-un-Nabi.

No official from the administration was available for comments on the issue.

"J&K administration has blocked the residence of Party President Dr Farooq Abdullah and stopped him from offering prayers at Dargah Hazratbal. JKNC condemns this infringement of fundamental right to pray, especially on the auspicious occasion of Milad Un Nabi SAW," the NC said on its Twitter handle.

Farooq Abdullah, who represents Srinagar in the Lok Sabha, was supposed to visit the Hazratbal shrine, on the banks of the Dal Lake, to pray there on the occasion.

Milad-un-Nabi marks the birth anniversary of Prophet Muhammad and it is observed in the month of Rabi' al-awwal, the third month in the Islamic calendar.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
October 17,2020

clinicaltrial.JPG

Moscow, Oct 17:  The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories Ltd have received renewed approval to conduct late-stage clinical trials in India of the Russian Covid-19 vaccine, the sovereign wealth fund said on Saturday.

Large-scale trials of the Sputnik V vaccine in India were first announced and then knocked back by Indian regulators, who said that the scale of Phase I and II trials conducted in Russia earlier this year was too small, requesting that they be repeated.

Following a new agreement, India will now carry out an adaptive phase II and III human clinical trial involving 1,500 participants, RDIF, which is marketing the vaccine abroad, said on Saturday.

Under the deal, Dr Reddy's will conduct the clinical trials and, subject to approval, distribute the finished vaccine in India. RDIF will supply 100 million doses to Dr Reddy's.

Russia, the first country to grant regulatory approval for a novel coronavirus vaccine, is also conducting Phase III trials of Sputnik V in Belarus, Venezuela and the United Arab Emirates.

RDIF has reached agreements with Indian manufacturers to produce 300 million doses of the shot.

A Phase III trial involving 40,000 participants is currently underway in Moscow, with 16,000 people having already received the first dose of the two-shot vaccine.

Interim results are expected to be published in early November.

Indian regulators have agreed to incorporate data, provided by Russia on a weekly basis, from the Moscow trial, a source close to the deal told Reuters.

Russia has also reached an agreement with the biotechnology department of India's Science and Technology Ministry to use its laboratories as a base for the Indian clinical trial, the source said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.